New generation calcium channel blockers in hypertensive treatment

Yuri Ozawa, Koichi Hayashi, Hiroyuki Kobori

研究成果: Review article査読

23 被引用数 (Scopus)


During a couple of decades, a number of antihypertensive drugs have been developed, and the choice of hypertension treatment has been expanded. Among antihypertensive drugs, calcium channel blockers, which inhibit L-type voltage-gated calcium channels, are potent vasodilators, and have been used as a first- or second-line drug. Dihydropyridine-class calcium channel blockers are categorized into three generations according to the length of activity, and long-acting calcium channel blockers cause less activation of sympathetic nervous system, and are reported to offer beneficial action compared with short-action agents. Furthermore, novel types of calcium channel blockers have been developed that possess the blocking action on other calcium channel subtypes (T- and N-type), and exert agent-specific action apart from their class effects, such as the effects on heart rate and renin/aldosterone release. These additional benefits conferred by T/N-type calcium channel blockade are anticipated to provide organ protective actions in the treatment of hypertension, in addition to the blood pressure-lowering effect of L-type calcium channel blockade. In conclusion, novel calcium channel blockers with sustained activity and T/N-type calcium channel blocking action could provide more beneficial effects than classical blockers, and may expand the clinical utility of these agents.

ジャーナルCurrent Hypertension Reviews
出版ステータスPublished - 2006 5月

ASJC Scopus subject areas

  • 内科学


「New generation calcium channel blockers in hypertensive treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。